T1	CHEM 375 382	GS-5734
#1	AnnotatorNotes T1	C4279131; GS-5734; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T2	CHEM 70 81	medicamento
#2	AnnotatorNotes T2	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T3	PROC 117 151	evaluar la seguridad y efectividad
T4	CHEM 156 167	medicamento
#3	AnnotatorNotes T4	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T5	PROC 174 185	tratamiento
#4	AnnotatorNotes T5	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T6	DISO 203 243	enfermedad grave por el coronavirus 2019
T7	PROC 278 308	Estudio de fase 3 aleatorizado
T8	PROC 314 334	evaluar la seguridad
#5	AnnotatorNotes T8	C1705187; Safety Study; Research Activity
T9	CHEM 363 373	remdesivir
#6	AnnotatorNotes T9	C4726677; remdesivir; Organic Chemical · Pharmacologic Substance
T10	DISO 406 437	infección grave por el COVID-19
T11	DISO 462 496	Enfermedad por el coronavirus 2019
#7	AnnotatorNotes T11	C5203670; COVID19 (disease); Disease or Syndrome
T12	PROC 636 650	procedimientos
#8	AnnotatorNotes T12	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T13	DISO 684 711	Infección por el SARS-CoV-2
#9	AnnotatorNotes T13	C5203670; COVID19 (disease); Disease or Syndrome
T14	PROC 577 613	consentimiento informado por escrito
#10	AnnotatorNotes T14	C0811741; Obtain informed written consent; Health Care Activity
T15	DISO 498 506	COVID-19
#11	AnnotatorNotes T15	C5203670; COVID19 (disease); Disease or Syndrome
T16	DISO 245 253	COVID-19
#12	AnnotatorNotes T16	C5203670; COVID19 (disease); Disease or Syndrome
T17	PROC 757 771	aleatorización
#13	AnnotatorNotes T17	C0034656; Randomization; Research Activity
T18	PROC 775 790	Hospitalización
#14	AnnotatorNotes T18	C0019993; Hospitalization; Health Care Activity
T19	DISO 795 801	fiebre
#15	AnnotatorNotes T19	C0015967; Fever; Sign or Symptom
T20	ANAT 849 854	axila
#16	AnnotatorNotes T20	C0004454; Axilla; Body Location or Region + C1279154; Entire axilla; Body Location or Region + C1283835; Entire axillary fossa; Body Location or Region
T21	ANAT 872 876	boca
#17	AnnotatorNotes T21	C0226896; Oral cavity; Body Space or Junction | C0230028; Oral region; Body Location or Region | C1267547; Entire mouth region; Body Space or Junction
T22	ANAT 895 900	recto
#18	AnnotatorNotes T22	C0034896; Rectum; Body Part, Organ, or Organ Component | C1278926; Entire rectum; Body Part, Organ, or Organ Component
T23	DISO 1559 1565	Signos
#19	AnnotatorNotes T23	C0311392; Physical findings; Finding
T24	DISO 983 1005	infiltrados pulmonares
#20	AnnotatorNotes T24	C0277877; Radiologic infiltrate of lung; Finding
T25	PROC 1132 1155	métodos anticonceptivos
#21	AnnotatorNotes T25	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T26	PROC 1176 1185	protocolo
#22	AnnotatorNotes T26	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T27	CHEM 102 109	GS-5734
#23	AnnotatorNotes T27	C4279131; GS-5734; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T28	PROC 1287 1301	ensayo clínico
#24	AnnotatorNotes T28	C0008976; Clinical Trials; Research Activity
T29	PROC 1308 1332	tratamiento experimental
#25	AnnotatorNotes T29	C2585119; Experimental therapeutic procedure; Therapeutic or Preventive Procedure
T30	PROC 1375 1399	tratamiento concomitante
#26	AnnotatorNotes T30	C1707479; Concomitant Therapy; Therapeutic or Preventive Procedure
T31	CHEM 1410 1450	fármacos con actividad antiviral directa
#27	AnnotatorNotes T31	C3653501; DIRECT ACTING ANTIVIRALS; Pharmacologic Substance
T32	PROC 904 908	SpO2
#28	AnnotatorNotes T32	C0428179; Measurement of oxygen saturation at periphery; Laboratory Procedure
T33	DISO 1343 1351	COVID-19
#29	AnnotatorNotes T33	C5203670; COVID19 (disease); Disease or Syndrome
T34	CHEM 1535 1542	fármaco
#30	AnnotatorNotes T34	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T35	DISO 1569 1596	insuficiencia multiorgánica
#31	AnnotatorNotes T35	C0026766; Multiple Organ Failure; Pathologic Function
T36	PROC 1613 1633	ventilación mecánica
#32	AnnotatorNotes T36	C0199470; Mechanical ventilation; Therapeutic or Preventive Procedure
T37	PROC 1717 1743	Aclaramiento de creatinina
#33	AnnotatorNotes T37	C0373595; Creatinine clearance measurement; Laboratory Procedure
T38	PROC 1759 1777	Prueba de embarazo
#34	AnnotatorNotes T38	C0032976; Pregnancy Tests; Diagnostic Procedure
T39	PROC 1788 1797	protocolo
#35	AnnotatorNotes T39	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T40	DISO 1834 1851	Hipersensibilidad
#36	AnnotatorNotes T40	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T41	CHEM 1864 1871	fármaco
#37	AnnotatorNotes T41	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T42	CHEM 1889 1900	metabolitos
#38	AnnotatorNotes T42	C0870883; Metabolite; Biologically Active Substance
T43	CHEM 1907 1918	excipientes
#39	AnnotatorNotes T43	C0015237; Pharmaceutical Excipient; Biomedical or Dental Material
T44	CHEM 90 100	remdesivir
#40	AnnotatorNotes T44	C4726677; remdesivir; Organic Chemical · Pharmacologic Substance
T45	PROC 732 735	PCR
#41	AnnotatorNotes T45	C0032520; Polymerase Chain Reaction; Molecular Biology Research Technique
T46	PROC 821 832	temperatura
#42	AnnotatorNotes T46	C0886414; Body temperature measurement; Health Care Activity
T47	ANAT 995 1005	pulmonares
#43	AnnotatorNotes T47	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T48	PROC 1516 1542	administración del fármaco
#44	AnnotatorNotes T48	C3469597; Administration of medication; Therapeutic or Preventive Procedure
T49	PROC 1661 1664	ALT
#45	AnnotatorNotes T49	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T50	PROC 1668 1671	AST
#46	AnnotatorNotes T50	C0201899; Aspartate aminotransferase measurement; Laboratory Procedure
T51	CHEM 1733 1743	creatinina
#47	AnnotatorNotes T51	C0010294; creatinine; Biologically Active Substance · Organic Chemical
T52	Date 13 17	2020
T53	LIVB 189 198	pacientes
#48	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group
T54	LIVB 227 243	coronavirus 2019
#49	AnnotatorNotes T54	C5203676; SARS-CoV-2; Virus
T56	LIVB 480 496	coronavirus 2019
#50	AnnotatorNotes T56	C5203676; SARS-CoV-2; Virus
T58	Age 671 680	≥ 18 años
T59	Duration 736 744	≤ 4 días
T61	LIVB 1027 1034	mujeres
#51	AnnotatorNotes T61	C0043210; Woman; Population Group
T62	PHYS 1039 1060	capacidad de procrear
#52	AnnotatorNotes T62	C3831118; Childbearing Potential; Clinical Attribute
T64	LIVB 1476 1486	SARS-CoV-2
#53	AnnotatorNotes T64	C5203676; SARS-CoV-2; Virus
T65	Duration 1490 1502	las 24 horas
T67	LIVB 1813 1830	Mujeres lactantes
#54	AnnotatorNotes T67	C0043210; Woman; Population Group + C4316174; Patients who are breastfeeding; Patient or Disabled Group
T70	PHYS 1769 1777	embarazo
#55	AnnotatorNotes T70	C0032961; Pregnancy; Organism Function
T55	LIVB 701 711	SARS-CoV-2
#56	AnnotatorNotes T55	C5203676; SARS-CoV-2; Virus
T57	LIVB 1013 1020	varones
#57	AnnotatorNotes T57	C0025266; Male population group; Population Group
T60	LIVB 388 401	participantes
#58	AnnotatorNotes T60	C4554048; Study Participant; Population Group
T63	PHYS 1821 1830	lactantes
#59	AnnotatorNotes T63	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
A1	Assertion T30 Contraindicated
A2	Assertion T31 Contraindicated
A3	Status T40 History_of
#60	AnnotatorNotes T6	C5439524; Acute COVID-19; Disease or Syndrome 
#61	AnnotatorNotes T10	C5439524; Acute COVID-19; Disease or Syndrome 
#62	AnnotatorNotes T7	C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity
R1	Used_for Arg1:T44 Arg2:T5	
R2	Used_for Arg1:T27 Arg2:T5	
R3	Used_for Arg1:T2 Arg2:T5	
R4	Used_for Arg1:T4 Arg2:T5	
R5	Experiences Arg1:T53 Arg2:T2	
R6	Experiences Arg1:T53 Arg2:T44	
R7	Experiences Arg1:T53 Arg2:T27	
R8	Experiences Arg1:T53 Arg2:T4	
R9	Experiences Arg1:T53 Arg2:T6	
R10	Experiences Arg1:T53 Arg2:T16	
R11	Causes Arg1:T54 Arg2:T6	
R12	Causes Arg1:T54 Arg2:T16	
R13	Experiences Arg1:T60 Arg2:T9	
R14	Experiences Arg1:T60 Arg2:T1	
R15	Experiences Arg1:T60 Arg2:T10	
R16	Causes Arg1:T56 Arg2:T11	
R17	Causes Arg1:T56 Arg2:T15	
T66	Observation 537 548	Disposición
#63	AnnotatorNotes T66	C0600109; Willing; Finding (?)
T68	Observation 551 560	capacidad
#64	AnnotatorNotes T68	C1299581; Able (finding); Finding (?) | C1555472; Authorized; Finding (?)
R18	Overlap Arg1:T68 Arg2:T14	
R19	Overlap Arg1:T66 Arg2:T14	
R20	Before Arg1:T14 Arg2:T12	
R21	Overlap Arg1:T66 Arg2:T12	
R22	Overlap Arg1:T68 Arg2:T12	
R23	Causes Arg1:T55 Arg2:T13	
R25	Overlap Arg1:T45 Arg2:T59	
R26	Before Arg1:T45 Arg2:T17	
T69	Result_or_Value 833 842	≥ 36,6 °C
R28	Has_Result_or_Value Arg1:T46 Arg2:T69	
R29	Location_of Arg1:T20 Arg2:T46	
T71	Result_or_Value 856 865	≥ 37,2 °C
R30	Has_Result_or_Value Arg1:T46 Arg2:T71	
R31	Location_of Arg1:T21 Arg2:T46	
T72	Result_or_Value 879 888	≥ 37,8 °C
R32	Location_of Arg1:T22 Arg2:T46	
R33	Has_Result_or_Value Arg1:T46 Arg2:T72	
R34	Location_of Arg1:T20 Arg2:T19	
R35	Location_of Arg1:T21 Arg2:T19	
R36	Location_of Arg1:T22 Arg2:T19	
T73	Result_or_Value 909 914	≤ 94%
T74	Quantifier_or_Qualifier 915 932	con aire ambiente
R37	Has_Quantifier_or_Qualifier Arg1:T32 Arg2:T74	
R38	Has_Result_or_Value Arg1:T32 Arg2:T73	
T75	PROC 947 956	selección
#65	AnnotatorNotes T75	C0242802; Patient Selection; Research Activity
R39	Overlap Arg1:T32 Arg2:T75	
R40	Location_of Arg1:T47 Arg2:T24	
T76	Observation 960 979	Signos radiológicos
R41	Overlap Arg1:T76 Arg2:T24	
R42	Location_of Arg1:T47 Arg2:T76	
T77	Observation 1075 1100	relaciones heterosexuales
#66	AnnotatorNotes T77	C0556476; Heterosexual relationship; Finding
R43	Experiences Arg1:T61 Arg2:T77	
R44	Experiences Arg1:T57 Arg2:T77	
R45	Before Arg1:T77 Arg2:T62	
R46	Overlap Arg1:T77 Arg2:T25	
R47	Experiences Arg1:T57 Arg2:T25	
R48	Experiences Arg1:T61 Arg2:T25	
T78	Observation 1255 1301	Participación en cualquier otro ensayo clínico
R50	Used_for Arg1:T31 Arg2:T30	
R51	Overlap Arg1:T31 Arg2:T65	
R52	Before Arg1:T30 Arg2:T48	
R53	Used_for Arg1:T34 Arg2:T48	
R54	Causes Arg1:T35 Arg2:T23	
T79	PROC 1648 1657	selección
#67	AnnotatorNotes T79	C0242802; Patient Selection; Research Activity
R55	Overlap Arg1:T36 Arg2:T79	
T80	Result_or_Value 1672 1713	> 5 x Límite Superior de Normalidad (LSN)
R56	Has_Result_or_Value Arg1:T50 Arg2:T80	
R57	Has_Result_or_Value Arg1:T49 Arg2:T80	
T81	Result_or_Value 1744 1755	< 50 mL/min
R58	Has_Result_or_Value Arg1:T37 Arg2:T81	
T82	Result_or_Value 1778 1786	positiva
#68	AnnotatorNotes T82	C1446409; Positive; Finding
R59	Has_Result_or_Value Arg1:T38 Arg2:T82	
R61	Experiences Arg1:T67 Arg2:T63	
R62	Causes Arg1:T41 Arg2:T40	
R63	Causes Arg1:T42 Arg2:T40	
R64	Causes Arg1:T43 Arg2:T40	
R65	Overlap Arg1:T18 Arg2:T46	
#69	AnnotatorNotes T3	C0511730; Identify product efficacy and safety issues; Health Care Activity
R24	Experiences Arg1:T57 Arg2:T62	
R27	Experiences Arg1:T61 Arg2:T62	
A4	Experiencer T57 Patient
A5	Experiencer T61 Patient
A6	Experiencer T53 Patient
A7	Experiencer T60 Patient
A8	Experiencer T67 Patient
